HTS07545

CAS No. 118666-03-8

HTS07545( —— )

Catalog No. M35541 CAS No. 118666-03-8

HTS07545 is a potent sulfide:quinone oxidoreductase inhibitor (IC50: 30 nM) that reduces the rate of hydrogen sulfide (H2S) decomposition and has been used in heart failure studies.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 Get Quote
5MG 85 Get Quote
10MG 140 Get Quote
25MG 273 Get Quote
50MG 440 Get Quote
100MG 618 Get Quote
500MG 1332 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    HTS07545
  • Note
    Research use only, not for human use.
  • Brief Description
    HTS07545 is a potent sulfide:quinone oxidoreductase inhibitor (IC50: 30 nM) that reduces the rate of hydrogen sulfide (H2S) decomposition and has been used in heart failure studies.
  • Description
    HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 decrease the rate of breakdown of hydrogen sulfide (H2S). HTS07545 can be used for heart failure research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    NADPH
  • Recptor
    NADPH
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    118666-03-8
  • Formula Weight
    358.39
  • Molecular Formula
    C22H18N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (279.03 mM; Ultrasonic )
  • SMILES
    C(#N)C=1C(=CC(=NC1OCC(OCC)=O)C2=CC=CC=C2)C3=CC=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Simon D P Baugh, et al. Synthesis and evaluation of potent novel inhibitors of human sulfide:quinone oxidoreductase. Bioorg Med Chem Lett. 2021 Dec 15;54:128443. ?
molnova catalog
related products
  • Obafistat

    Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC 50 of 1.2 nM for human AKR1C3 .

  • Acetohexamide

    Acetohexamide is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2.

  • AKR1C3-IN-4

    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC 50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.